Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors

Inclusion Criteria: 1. Fully understand this trial and voluntarily sign the informed consent form; 2. Advanced solid tumors diagnosed by histology or cytopathology; 3. Be able to provide archived (within 2 years after the first treatment with study drug) or fresh tumor tissue samples for relevant biological sample analysis required by the protocol; 4. At least one measurable lesion according to RECIST Version 1.1 (patients with only brain lesion as target lesion are not accepted); 5. Eastern United States Oncology Assistance Group (ECOG) performance status score of 0 or 1; 6. The expected survival time is more than 3 months; 7. Adequate organ and bone marrow function 8. Females of childbearing potential must have a negative blood pregnancy test within 7 days prior to the first dose of investigational product and be non-lactating; Eligible patients of childbearing potential (male and female) must agree to use a reliable method of contraception (hormonal or barrier method or abstinence) with their partner for at least 6 months from signing informed consent until after the last dose of study drug. Women of non-childbearing potential may not undergo pregnancy test and contraception (postmenopausal for at least 1 year or surgically sterilized). Exclusion Criteria: 1. Patients with imaging findings showing tumor invasion of great vessels or unclear demarcation from blood vessels; 2. Patients with combined brain metastasis, meningeal metastasis, spinal cord compression or leptomeningeal disease; 3. Previous treatment with monoclonal antibodies, bispecific antibodies, small molecule compounds and cells targeting CCR8 at any time; 4. Conditions may significantly affect the autoimmune status; 5. Patients with serious, uncontrolled and unrecoverable acute and chronic diseases: 6. Subjects with other malignant tumors within 5 years prior to the first dose of the investigational drug ; 7. Subjects who have undergone major organ surgery (excluding aspiration biopsy) within 4 weeks prior to the first dose of study drug, or have experienced significant trauma, or require elective surgery during the trial;